Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Inflammation A Clue Left In ACCELERATE CETP Wreckage

Executive Summary

Blood pressure and C-reactive protein were modestly increased in the ACCELERATE trial of Lilly’s CETP inhibitor evacetrapib, but what exactly torpedoed the trial is still a mystery.


Related Content

Merck Loses Chance For Primary Care Blockbuster With Odanacatib Failure
Where Cholesterol Surrogates Stand After ACC '16
Dalcetrapib Failure Raises Yet More Questions On Value Of Tinkering With HDL Cholesterol
Pfizer’s Lipitor Extension Shot Down By Failure Of Torcetrapib Silver Bullet


Related Companies